English | Español
Press release submission | Jan 6, 2022

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

Press release submission | Jan 5, 2022

NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Bree Gonzales | Jan 5, 2022

Biden: 'We’re mobilizing an additional 1,000 military doctors and nurses to help staff hospitals'
Bree Gonzales | Jan 4, 2022

The No Surprises Act took effect Jan. 1: 'Its effect will eventually be felt by literally everybody'
Bree Gonzales | Jan 4, 2022

Vaccine mandate for domestic air travel is not off the table: 'You want to keep people safe'
Bree Gonzales | Jan 3, 2022

Health experts challenge CDC’s new isolation guidelines despite 'sheer volume of new cases'
Press release submission | Dec 29, 2021

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Press release submission | Dec 29, 2021

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Trending
+ Pharmaceuticals
Patient Daily | Oct 23, 2025

Empower seeks dismissal of Eli Lilly suit in Texas federal court
Patient Daily | Oct 23, 2025

Dallas Breathe Free ENT Specialist: Humidity 'tends to help' with sinus issues
+ Pharmaceuticals
Patient Daily | Oct 29, 2025

Paragon Health Institute senior fellow: 340B program 'needs real reform'
Patient Daily | Oct 23, 2025

Capitol Breathe Free Otolaryngologist: ‘Allergy exacerbations are a common trigger for sinus infections'